Loading clinical trials...

Effects of PEA-LUT on Frontal Lobe Functions and GABAergic Transmission in Long-Covid Patients | Clinical Trials | Clareo Health

COMPLETEDNA

Effects of PEA-LUT on Frontal Lobe Functions and GABAergic Transmission in Long-Covid Patients

Effects of Palmitoylethanolamide Co-ultramicronized With Luteoline (Pea-lut) on Frontal Lobe Functions and GABAergic Transmission in Long Covid Patients. An 8-week Randomized Controlled Trial.

NCT05311852•Department of Neurorehabilitation, Hospital of Vipiteno-Sterzing (BZ) Italy

View on ClinicalTrials.gov

Summary

The study explore the efficacy of PEA-LUT in patients suffering from neurological symptoms of Long-Covid

Detailed Description

Aim of this study was testing the possible therapeutic effects of an 8-week therapy with PEA-LUT on GABAB-ergic neurotransmission, LTP-like synaptic plasticity, indexed with transient potentiation of motor evoked potentials (MEP) amplitude after repetitive TMS given as intermittent theta burst stimulation (iTBS) in long COVID patients with cognitive complaints and fatigue.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•previous diagnosis of SARS-CoV-2 infection confirmed through detection of virus RNA by polymerase chain reaction (PCR) testing of a nasopharyngeal swab;
•subsequent recovery from infection as defined by two consecutive negative PCR tests separated by at least a day;
•mild form of COVID-19 (symptoms may include fever, cough, sore throat, malaise, myalgia, anorexia, nausea, diarrhoea, anosmia and ageusia) without necessitating hospital admission;
•complaints of cognitive difficulties and/or sense of fatigue, persisting after SARS-CoV-2 infection.

Exclusion Criteria

•prior or concurrent diagnosis of neurological, psychiatric, endocrine, metabolic or cardiopulmonary conditions;
•clinical and/or radiological evidence of COVID-19 related pneumonia during the active phase of the disease;
•anaemia;
•current pharmacological treatment with corticosteroids, antihistamines, antihypertensives, diuretics, antidepressants, anxiolytic or hypnotic drugs at the time of study

Locations (1)

Hospital of Vipiteno-Sterzing

Sterzing, BZ, Italy

Key Dates

Start Date

August 16, 2021

Primary Completion Date

February 15, 2022

Completion Date

March 15, 2022

Last Updated

September 26, 2022

Enrollment

ACTUAL participants

Conditions

FatigueCognitive DeficitCOVID-19Neurophysiologic Abnormality

Interventions

palmitoylethanolamide co-ultramicronized with antioxidant flavonoid luteolin (PEA-LUT)

DIETARY_SUPPLEMENT

Placebo

DIETARY_SUPPLEMENT

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162

COVID-19

View study

RECRUITINGNA

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 26, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects of PEA-LUT on Frontal Lobe Functions and GABAergic Transmission in Long-Covid Patients

Inclusion Criteria

Exclusion Criteria

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

Dime La VerDAD: Verify, Debunk, and Disseminate